Overview

Price chart · mood · technical indicators

ABBV

AbbVie Incstock Healthcare

Drug Manufacturers - General

$208.2011.24%Current Market Mood:Bearish

Market Mood

Price Range (1Y)

$176.57$244.81

Current: $208.20

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

ABBV

+11.24%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio100.78Forward 14.49

EPS (TTM)$2.05-45.8% YoY

Profit margin5.8%HEALTHCARE

Market cap$365.43BMega cap

Wall Street coverage

$250.33median target· current $162.73 (+53.8%)32 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 14.49
PEG ratio: 0.57
P/B: 50.46
P/S (TTM): 5.82
EV/EBITDA: 48.53

Profitability & growth

ROE (TTM): 62.3%
Operating margin: 31.6%
Revenue growth YoY: 12.4%
Dividend yield: 3.2%
Beta: 0.36

Last earnings

Apr 23, 2026 · Estimate $3.01 · Reported $2.65

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About AbbVie Inc

Company profile

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$365.43B

Shares outstanding$1.77B

52W high$239.13

52W low$171.00

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

ABBV

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

Vanguard Group Inc. Sells 233,525 Shares of ACI Worldwide, Inc. $ACIW

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

Intact Investment Management Inc. Raises Stake in Kimberly-Clark Corporation $KMB

Tenax brings in drug launch veteran Timothy Healey to prep TNX-103

Cullinan Associates Inc. Purchases 7,051 Shares of Johnson & Johnson $JNJ

How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal

VELA Investment Management LLC Makes New $3.10 Million Investment in Gildan Activewear, Inc. $GIL

Kornitzer Capital Management Inc. KS Acquires 5,020 Shares of AbbVie Inc. $ABBV

5,538 Shares in AbbVie Inc. $ABBV Acquired by Legacy Edge Advisors LLC

AbbVie Inc. $ABBV Shares Sold by PKO Investment Management Joint Stock Co

Horizon Investments LLC Sells 48,862 Shares of Abbott Laboratories $ABT

Did Amgen’s Raised 2026 Outlook and AI-Focused Overhaul Just Shift AMGN’s Investment Narrative?

MannKind (MNKD) Expected to Announce Quarterly Earnings on Wednesday

Strs Ohio Has $181.81 Million Position in AbbVie Inc. $ABBV

PFA Pension Forsikringsaktieselskab Makes New Investment in Abbott Laboratories $ABT

PFA Pension Forsikringsaktieselskab Buys New Shares in AbbVie Inc. $ABBV

Artemis Investment Management LLP Has $160.86 Million Stock Position in AbbVie Inc. $ABBV

About AbbVie Inc

Classification

Company profile

ABBV

Market Comparison

ABBV Market Analysis

Overview

ABBV

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

Vanguard Group Inc. Sells 233,525 Shares of ACI Worldwide, Inc. $ACIW

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

Intact Investment Management Inc. Raises Stake in Kimberly-Clark Corporation $KMB

Tenax brings in drug launch veteran Timothy Healey to prep TNX-103

Cullinan Associates Inc. Purchases 7,051 Shares of Johnson & Johnson $JNJ

How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal

VELA Investment Management LLC Makes New $3.10 Million Investment in Gildan Activewear, Inc. $GIL

Kornitzer Capital Management Inc. KS Acquires 5,020 Shares of AbbVie Inc. $ABBV

5,538 Shares in AbbVie Inc. $ABBV Acquired by Legacy Edge Advisors LLC

AbbVie Inc. $ABBV Shares Sold by PKO Investment Management Joint Stock Co

Horizon Investments LLC Sells 48,862 Shares of Abbott Laboratories $ABT

Did Amgen’s Raised 2026 Outlook and AI-Focused Overhaul Just Shift AMGN’s Investment Narrative?

MannKind (MNKD) Expected to Announce Quarterly Earnings on Wednesday

Strs Ohio Has $181.81 Million Position in AbbVie Inc. $ABBV

PFA Pension Forsikringsaktieselskab Makes New Investment in Abbott Laboratories $ABT

PFA Pension Forsikringsaktieselskab Buys New Shares in AbbVie Inc. $ABBV

Artemis Investment Management LLP Has $160.86 Million Stock Position in AbbVie Inc. $ABBV

About AbbVie Inc

Classification

Company profile

ABBV

Market Comparison